Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Amylyx Pharmaceuticals (AMLX) with a $44 price target. This follows H.C. Wainwright's August 20 report, which also reiterated a Buy rating and set a higher $55 price target for the stock.
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Amylyx Pharmaceuticals Inc today and set a price target of $44.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Katkhuda covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Disc Medicine, and Vera Therapeutics. According to TipRanks, Katkhuda has an average return of 34.4% and a 56.32% success rate on recommended stocks.
In a report released on August 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $55.00 price target.